SCHEMBL20451990

SCHEMBL20451990

CNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCN(Cc5ccccc5)CC4)cn3)n2)s1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.80
CDK4 P11802 18/20 0.68
CCND1 P24385 17/20 0.68
CCND3 P30281 17/20 0.68
CDK6 Q00534 17/20 0.68
CDK9 P50750 15/20 0.65
CCNT1 O60563 13/20 0.65
CDK7 P50613 13/20 0.65
CCNH P51946 12/20 0.65
CDK1 P06493 10/20 0.65
CCNB1 P14635 9/20 0.65
CDK2 P24941 15/20 0.64
CCNA2 P20248 13/20 0.64
AURKA O14965 2/20 0.56
AURKB Q96GD4 2/20 0.56
CHEK1 O14757 1/20 0.55
DAPK3 O43293 1/20 0.55
JAK2 O60674 1/20 0.55
PRKD3 O94806 1/20 0.55
PAK4 O96013 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2077092 0.89 GSK3B (1.00) GSK3BCDK4CCND1CCND3CDK6
SCHEMBL20452096 0.86 CDK4 (0.81) CDK4CCND1CCND3CDK6CDK9
SCHEMBL29815412 0.86 CDK4 (0.81) CDK4CCND1CCND3CDK6CDK9
SCHEMBL20452142 0.84 CCNA2 (0.59) GSK3BCDK4CCND1CCND3CDK6
SCHEMBL29815829 0.83 CDK4 (0.82) GSK3BCDK4CCND1CCND3CDK6
SCHEMBL18480846 0.83 CDK4 (0.82) GSK3BCDK4CCND1CCND3CDK6
SCHEMBL20451995 0.83 CDK4 (0.82) CDK4CCND1CCND3CDK6CDK9
SCHEMBL30777167 0.83 CDK4 (0.82) CDK4CCND1CCND3CDK6CDK9
SCHEMBL4168788 0.83 GSK3B (0.88) GSK3BCDK4CCND1CCND3CDK6
SCHEMBL20452030 0.82 CDK2 (0.83) GSK3BCDK4CCND1CCND3CDK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059178-A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS Aucentra Thereapeutics Pty LTD (AU) 2025-02-20 US disclosed
US-11970491-B2 N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds AUCENTRA THERAPEUTICS PTY LTD (AU) 2024-04-30 US disclosed
US-RE49850-E1 N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds AUCENTRA THERAPEUTICS PTY LTD (AU) 2024-02-27 US disclosed
US-RE49850-E1 N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds AUCENTRA THERAPEUTICS PTY LTD (AU) 2024-02-27 US disclosed
US-RE49850-E1 N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds AUCENTRA THERAPEUTICS PTY LTD (AU) 2024-02-27 US disclosed
EP-3957637-B1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS AUCENTRA THERAPEUTICS PTY LTD (AU) 2023-06-28 EP disclosed
EP-3957637-B1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS AUCENTRA THERAPEUTICS PTY LTD (AU) 2023-06-28 EP disclosed
EP-3331880-B3 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS AUCENTRA THERAPEUTICS PTY LTD (AU) 2023-01-11 EP disclosed
US-20220267315-A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS AUCENTRA THERAPEUTICS PTY LTD (AU) 2022-08-25 US disclosed
EP-3957637-A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS Aucentra Therapeutics Pty Ltd (AU) 2022-02-23 EP disclosed
EP-3331880-B1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS AUCENTRA THERAPEUTICS PTY LTD (AU) 2021-12-01 EP disclosed
US-20200283431-A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS AUCENTRA THERAPEUTICS PTY LTD (AU) 2020-09-10 US disclosed
US-20200283431-A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS AUCENTRA THERAPEUTICS PTY LTD (AU) 2020-09-10 US disclosed
US-10479785-B2 N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds AUCENTRA THERAPEUTICS PTY LTD (AU) 2019-11-19 US disclosed
US-10479785-B2 N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds AUCENTRA THERAPEUTICS PTY LTD (AU) 2019-11-19 US disclosed
US-20180222900-A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS AUCENTRA THERAPEUTICS PTY LTD (AU) 2018-08-09 US disclosed
US-20180222900-A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS AUCENTRA THERAPEUTICS PTY LTD (AU) 2018-08-09 US disclosed
US-20180222900-A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS AUCENTRA THERAPEUTICS PTY LTD (AU) 2018-08-09 US disclosed
US-20160068497-A1 Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia H. LUNDBECK A/S (DK) 2016-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180222900-A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS CDK4, CDK6, CDK2 GSK3B 711/4885CDK4 1/4885CCND1 17/4885
US-20160068497-A1 Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia HTR2C, DRD2, HTR2A GSK3B 2368/4885CDK4 773/4885CCND1 690/4885
US-20250059178-A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS CDK4, CDK6, CDK2 GSK3B 710/4885CDK4 1/4885CCND1 14/4885
US-10479785-B2 N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds CDK4, CDK6, CDK2 GSK3B 711/4885CDK4 1/4885CCND1 17/4885
US-20200283431-A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS CDK4, CDK6, CDKL2 GSK3B 733/4885CDK4 1/4885CCND1 17/4885
US-11970491-B2 N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds CDK4, CDK6, CDK3 GSK3B 976/4885CDK4 1/4885CCND1 18/4885
US-20220267315-A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS CDK4, CDK6, CDK3 GSK3B 976/4885CDK4 1/4885CCND1 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.